Clinical

Dataset Information

0

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors


ABSTRACT: This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.

DISEASE(S): Ovarian Cancer,Colorectal Cancer,Solid Tumors

PROVIDER: 2348111 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2393100 | ecrin-mdr-crc
| 2182785 | ecrin-mdr-crc
| 2348838 | ecrin-mdr-crc
| 2210681 | ecrin-mdr-crc
2022-01-28 | PXD028109 | Pride
| phs001707 | dbGaP
2019-11-07 | PXD007086 | Pride
2019-11-07 | PXD007085 | Pride
| 10773 | ecrin-mdr-crc
| PRJNA448188 | ENA